Tarsus to Participate in Upcoming Investor Conference
Tarsus Pharmaceuticals, Inc. (NASDAQ: TARS), today announced that management will participate in a fireside chat at the ...
Why eye health is the next wellness frontier and what you should be doing about yours
One additional area you might not be thinking about but should be is eye health. Like other significant systems in the body, ...
Focus on Eyes: Burning, stinging eyes? Dry eye disease could be the cause
The mucus comes from the conjunctiva which is the transparent tissue covering the whites of the eye and internal surface of ...
Morningstar2d
Tarsus to Participate in Upcoming Investor Conference
is FDA approved in the United States for the treatment of Demodex blepharitis. Tarsus is also developing TP-04 for the potential treatment of Ocular Rosacea and TP-05 as an oral tablet for the ...
Johns Hopkins Medicine4d
Ocular Surface Disease and Dry Eye Clinic
We strive to provide excellent medical management, eyelid procedures, and PROSE treatment/scleral ... IPL treats Meibomian Gland Dysfunction (MGD), especially when associated with Ocular Rosacea. The ...
Medscape5d
Rosacea: Newer Approaches to Diagnosis, Management
Rosacea treatment is a marathon — not a sprint — and there’s a need for increased emphasis on a patient-centric approach to ...
CNET on MSN6d
Rosacea: Symptoms, Causes and 5 Skincare Treatment Tips
You likely wash your face twice a day, and that's exactly what your dermatologist wants you to do. Having rosacea poses an ...
CNN1d
Tarsus Pharmaceuticals, Inc.
Its product candidate, TP-03, is a novel therapeutic in Phase 2b/3 that is being developed for the treatment of blepharitis caused by the infestation of Demodex mites, which is referred to as ...